Lucid Diagnostics Sustainability Accounting Standards Board Index

Lucid Diagnostics is proud to present 2023 annual Sustainability Accounting Standards Board (SASB) index with focus on Medical Equipment and Supplies. We recognize providing transparent financial input and relevant company responsibility towards sustainability is critical to investors and stakeholders. We seek to continue to drive meaningful difference towards sustainability and social needs while driving business value. Data provided in this report is reflected from the calendar year of 2023, unless stated otherwise.

TOPIC	CODE	SASB Metric	2023 Reporting
Affordability and Pricing	SASB HC-MS-240a.2	Description of how price information for each product is disclosed to customers or to their agents	Price Information Disclosure: The boundaries of our pricing guidelines for our medical technologies are largely governed by third-party health insurance carriers and must fit within those boundaries to be economically viable for clinical providers and therefore affordable for patient access. Consequently, price information disclosure is very transparent because of health care insurance economic influence on customer decisions.

TOPIC	CODE	SASB Metric	2023 Reporting
Affordability and Pricing	SASB HC-MS-240a.1	Ratio of weighted average rate of net price increases (for all products) to the annual increase in the U.S. Consumer Price Index	Price Increases: 0 Please refer to our annual report on Form 10-K as filed with the SEC noting relevant disclosures regarding contractual agreements with manufacturers and customers and certain risk factors that may impact product pricing. Furthermore, our marketing strategies are governed by honesty and transparency, consistent with our Company values and Code of Ethics. Additionally, the boundaries of our pricing guidelines for our medical technologies are largely governed by third-party health insurance carriers and must fit within those boundaries to be economically viable for clinical providers and therefore affordable for patient access.

TOPIC	CODE	SASB Metric	2023 Reporting
Business Ethics	SASB HC-MS-510a.1	Total amount of monetary losses as a result of legal proceedings associated with bribery or corruption	Monetary Losses as a Result of Legal Proceedings: 0 There have been no corporate monetary losses as a result of any domestic or foreign corrupt practices ever in the history of the Company. The Company has a robust COSO framework as provided for in compliance with the Sarbanes Oxley Act (Sox control environment). Furthermore, the company uses an outside party (BDO accountants) to test the reliability of and the compliance with the comprehensive system of internal controls and annually issues a report to the Company's audit committee detailing the testing results and whether there are any deficiencies noted in the design of the controls or whether the controls designed were not operating effectively. Additionally, the Sox controls includes a robust set of controls specifically designed to assure that any fraud, errors, or irregularities will not go undetected. BDO's testing of those controls includes not only the detail inspection of documents but also includes interviews with key leadership and directors where the risk of potential fraud could exist.

TOPIC	CODE	SASB Metric	2023 Reporting
Business Ethics	SASB HC-MS-510a.2	Description of code of ethics governing interactions with health care professionals	Health Care Professionals Code of Ethics: Refer to PAVmed's Sunshine Act policy, its published Code of Ethics on its website, and the Employee Handbook for instruction on expected behavior by all employees, and particularly Health Care Professionals. In addition, PAVmed (Lucid Diagnostics' parent company) is a signatory on the AdvaMed Code of Ethics. As a company that is part of AdvaMed association, it signifies that the company adheres to the codes stated by AdvaMed and has implemented an effective compliance program.
Ethical Marketing	SASB HC-MS-270a.2	Description of code of ethics governing promotion of off-label use of products	Off-label Use Code of Ethics: We do not promote off-label use.

TOPIC	CODE	SASB Metric	2023 Reporting
Ethical Marketing	SASB HC-MS-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	Amount of Monetary Losses: 0 Lucid Diagnostics had no monetary losses due to legal proceedings due to false marketing claims or monetary liabilities to others.
Product Design & Lifecycle Management	SASB HC-MS-410a.2	Total amount of products accepted for takeback and reused, recycled, or donated, broken down by: (1) devices and equipment and (2) supplies	Number of Products Accepted for Takeback and Reused, Recycled, or Donated: 0 Zero products and supplies have been accepted for takeback. Continual efforts are made to evaluate longer useful life of product performance and where feasible implement device reprocessing procedures.

TOPIC	CODE	SASB Metric	2023 Reporting
Product Design & Lifecycle Management	SASB HC-MS-410a.1	Discussion of process to assess and manage environmental and human health considerations associated with chemicals in products, and meet demand for sustainable products	Process to Assess and Manage Environmental and Human Health: Lucid Diagnostics periodically assesses its processes to review opportunities to minimize negative environmental and human health impacts. Our current practices focus on material, supply chain, and animal welfare processes. Lucid Diagnostics carefully selects non-toxic materials for its products and monitors opportunities to minimize product waste. All products are tested for biocompatibility including toxicology testing to ensure all materials are safe for the intended human use and minimize environmental harm. Lucid Diagnostics' parent company, PAVmed, has made significant advancements such as obtaining FDA clearance for EsoCheck, a cell collection device, without the sterilization requirement previously mandated. In addition, Lucid Diagnostics continually evaluates removal of unnecessary packing materials, like shelf boxes, and integrates this practice into its devices where possible. We also have moved to removal of paper IFUs from our packaging in favor of eIFUs and condensed paper materials where regulation allows and feasible to introduce. In addition to material usage monitoring, Lucid Diagnostics continually evaluates other opportunities for efficiency including alternative sterilization options that minimize supply chain logistics and additional processing associated with environmental impact. Finally, Lucid Diagnostics minimizes animal testing where possible by exploring alternative bench test models and designing tests to minimize the number of animals required. When animal testing is required, Lucid Diagnostics ensures the standard of care of animal welfare is achieved by utilizing Institutional Animal Care and Use Committees (IACUCs) that adhere to the Animal Welfare Act of the U.S. Public Health Service and The NIH Office of Laboratory Animal Welfare (OLAW) policies. Ongoing efforts will be made to assess additional opportunities to track and minimize environmental and human health impacts.

TOPIC	CODE	SASB Metric	2023 Reporting
Product Safety	SASB HC-MS-250a.1	Number of recalls issued, total units recalled	Number of Recalls: 0 There have been no voluntary and/or mandated recalls for product distributed by Lucid Diagnostics through 2023.
Product Safety	SASB HC-MS-250a.4	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	Number of FDA Enforcement Actions Taken: 0 There have been no enforcement actions taken by the FDA.
Product Safety	SASB HC-MS-250a.2	List of products listed in the FDA's MedWatch Safety Alerts for Human Medical Products database	Products Listed in the FDA's MedWatch Safety Alerts: None. There have been no reported product listed in MedWatch Safety Alerts for Human Medical Products under Lucid Diagnostics. We report all necessary data as required by FDA.
Product Safety	SASB HC-MS-250a.3	Number of fatalities related to products as reported in the FDA Manufacturer and User Facility Device Experience	Number of Fatalities Related to Products: 0 There have been no reported fatalities as a result of using product by Lucid Diagnostics. We report all necessary data as required by FDA.

TOPIC	CODE	SASB Metric	2023 Reporting
Supply Chain Management	SASB HC-MS-430a.3	Description of the management of risks associated with the use of critical materials	Critical Material Risk Management: Lucid Diagnostics is evaluating suppliers and their capability of maintaining supplies and inventory to minimize risk to supply chain. In addition, Lucid Diagnostics continues to seek new suppliers for dual sourcing while maintaining strong relationship with existing suppliers. This is by means of upfront forecast/demand planning and frequent communication.
Supply Chain Management	SASB HC-MS-430a.2	Description of efforts to maintain traceability within the distribution chain	Efforts to Maintain Traceability: Lucid Diagnostics requires traceability from the component level to finished good manufacturing. This is required from component supplier, contract manufacturer, service provider, and distribution centers. This is required per Lucid Diagnostics' quality system and respective quality agreements.
Supply Chain Management	SASB HC-MS-430a.1	Percentage of (1) entitys facilities and (2) Tier I suppliers facilities participating in third-party audit programs for manufacturing and product quality	Percentage of facilities and tier I suppliers facilities participating in third-party audits: 100 PAVmed and subsidiary Lucid Diagnostics are audited annually to ISO 13485:2016 and uphold certification to that standard. Tier 1 suppliers are assessed by criticiality level. All suppliers at Level 1 (critical) requires ISO certification and/or industry specific accreditations and are audited every 2 years. Suppliers at Level 2 and 3 are assessed per our quality system requirements.